INITIATE

Our Ventures team supports the launch of startups based on University of Michigan technologies and research discoveries. We provide a full suite of resources, services and funding to help you launch sustainable, impactful world changing startups. The Ventures team will engage with you from day one to establish clear and executable commercialization, business formation and funding strategies. As your startup project begins to take form we can provide grant funding and investment capital, as well as business know-how, talent resources and connections to a nationwide network of investors. Whether it is helping you find the perfect team member, investment partner or connecting you with service providers, we have you covered.

We are in the age of discovery, seizing a unique moment in time. Every generation experiences a breakthrough that alters the world. Technology has transformed virtually every aspect of our lives, and now it’s healthcare’s turn. aMoon is here to accelerate this transformation. We partner with exceptional entrepreneurs who harness groundbreaking science and technology to transform healthcare. Through aMoon Velocity and aMoon Growth, we invest in early and late-stage companies pursuing disruptive, cutting-edge solutions for high unmet medical needs. We build bridges between our portfolio companies and global tech, finance and medical research hubs to enable entrepreneurs to turn their vision into reality.

Fåhraeus Startup and Growth Fund was started in 2021 by Christer Fåhraeus and Emanuel Eriksson. It is a Venture Capital fund focusing on investing early in companies in life science and tech. The goal of the investments is to take the companies up for sale or listing on the stock exchange a few years after the investment. Christer and Emanuel, together with Linus Wiebe, manage the fund. History of the fund In recent years, Christer Fåhraeus and Emanuel Eriksson have worked together with investments in small listed companies and unlisted life science and tech companies for Fårö Capital. Fårö Capital is a Family Office fund where Christer has been CEO and Emanuel Investment Manager. During the years at Fårö Capital, they decided to raise a fund for investments in companies in the same industry with excellent growth potential. Sustainability Fåhraeus Startup & Growth has integrated sustainability risks into the investment decision process at all stages of the investment life cycle. Sustainability risks include environmental, social or governance-related events or circumstances that may have a significant adverse effect on the value of the investment. The risks are initially assessed together with other types of risks as part of the due diligence work before the investment takes place. The various factors are prioritized depending on how important they are for the business, the stakeholders and the expected effect on the investment. A conclusion that there are significant sustainability risks that will not be manageable or limited results in a decision not to invest. Fåhraeus Startup & Growth does not consider the main negative consequences of investment decisions for sustainability factors because, given the fund’s size and investment strategy, it is not possible to carry out reliable due diligence from a cost-benefit perspective. However, the fund continues to evaluate and consider its obligations regarding the investments’ main negative consequences for sustainability factors. Decisions and publications can be reviewed once the technical standards have been adopted and when data and tools for measuring the significant negative consequences regarding unlisted life science and technology companies have been developed and become more efficient. Before making an investment decision, the long-term effects of the investment are taken into account, and the fund avoids taking short-term risks to achieve a profit.

Since its genesis at the University of Oxford in 2015, Panacea Innovation has partnered with some of the world’s best sci-entrepreneurs, research bodies, universities and corporates to build more than 280 companies that offer cutting-edge solutions - curating a portfolio of more than GBP£300m in value. Panacea Innovation’s venturing activities are delivered through two complementary arms: Panacea Stars - a technology translation, commercialisation and R&D arm - and Panacea Ventures, the investment management one.

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our team is made up of life science experts and business analysts that can guide life science companies’ development throughout the entire research and development process. BioGeneration Ventures leverages its knowledge gained from working with a diverse network. This includes universities, early stage biotech companies and large pharma. We enable a range of sector-relevant expertise to build and accelerate product development and transform entrepreneurs and their companies to become attractive investment opportunities within the life sciences industry. Our Strategy BioGeneration Ventures (BGV) was launched in 2006. We manage over EUR 250 million across four funds. BGV invests in medical and healthcare innovations that have high potential to positively impact patients. BGV works with an ethos founded in sound novel science. We seek those innovations that have a truly differentiated scientific basis, supported by convincing experimental data. These innovations must be compelling and stand out in the global scientific arena. Only innovations that can address a significant unmet medical need are considered for investment. We aspire to invest in solutions that provide substantial healthcare impact. Progressing a project from discovery to clinical proof-of-concept requires a breadth of experience that founding teams usually do not have from the outset. Through our extensive network and experience we help founders build their companies to extend their capabilities. We guide our portfolio companies along their journey from the scientific discovery to a targeted product development track. Together with the founders, we seeks to shape the companies and define the objectives that enable a successful exit. Our partnerships BGV invests in partnerships with other professional investors in life sciences and has built relationships with various academic institutions (such as Leiden University), venture capital investors in the Netherlands, the EU and the US. Forbion: BGV operates a joint venture partnership with Forbion, a leading European life sciences venture capital fund. Mibiton: Mibiton provides loans to enable promising young life sciences companies to purchase equipment. BGV actively supports the investment activities with BGV Managing Partner Edward van Wezel serving as a member of the board. Our Investors: BGV has a broad investor base comprising private equity/wealth managers, pension funds, academic institutions, regional development funds and private investors.

Biospring Partners was founded in 2020 to invest in companies with the potential to fundamentally shift how technology is utilized across the life sciences sector. Michelle Dipp and Jennifer Lum came together to combine their experience in healthcare, technology, investing and operations to offer a differentiated approach to growth equity. Expanding the potential of life sciences technology We focus on identifying long-term themes within life sciences technology. We build trusted partnerships with management teams to support the growth of their businesses. Sectors we invest in Biospring invests in growth-stage B2B companies that are driving innovation across the life sciences industry and beyond. Our Approach We are a trusted partner that thrives in building long term strategic partnerships. We work closely alongside our companies to broaden their ambition and strengthen their path to growth. Our Investment Criteria$10M+ in annual revenue 30%+ revenue growth Diverse customer base